keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/27933281/pet-imaging-of-urokinase-type-plasminogen-activator-receptor-upar-in-prostate-cancer-current-status-and-future-perspectives
#1
REVIEW
Dorthe Skovgaard, Morten Persson, Andreas Kjaer
Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an important biomarker for aggressiveness in most common malignant diseases, including prostate cancer (PC). Accordingly, uPAR expression either assessed directly in malignant PC tissue or assessed directly in plasma (intact/cleaved forms)-provides independent additional clinical information to that contributed by PSA, Gleason score, and other relevant pathological and clinical parameters. In this respect, non-invasive molecular imaging by positron emission tomography (PET) offers a very attractive technology platform, which can provide the required quantitative information on the uPAR expression profile, without the need for invasive procedures and the risk of missing the target due to tumor heterogeneity...
2016: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27933280/bone-imaging-in-prostate-cancer-the-evolving-roles-of-nuclear-medicine-and-radiology
#2
REVIEW
Gary J R Cook, Gurdip Azad, Anwar R Padhani
The bone scan continues to be recommended for both the staging and therapy response assessment of skeletal metastases from prostate cancer. However, it is widely recognised that bone scans have limited sensitivity for disease detection and is both insensitive and non-specific for determining treatment response, at an early enough time point to be clinically useful. We, therefore, review the evolving roles of nuclear medicine and radiology for this application. We have reviewed the published literature reporting recent developments in imaging bone metastases in prostate cancer, and provide a balanced synopsis of the state of the art...
2016: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27932557/quantitative-parameters-in-psma-targeted-pet-imaging-with-18f-dcfpyl-variability-in-normal-organ-uptake
#3
Xin Li, Steven P Rowe, Jeffrey P Leal, Michael A Gorin, Mohamad E Allaf, Ashley E Ross, Kenneth J Pienta, Martin A Lodge, Martin G Pomper
PURPOSE: (18)F-DCFPyL is a small-molecule inhibitor of the prostate-specific membrane antigen (PSMA) that has shown promise for evaluation of primary and metastatic prostate cancer (PC) using positron emission tomography (PET). Measuring the variability in normal organ uptake of (18)F-DCFPyL is necessary to understand its biodistribution, aid image interpretation, judge the reliability of scan quantification, and to provide a basis for therapeutic monitoring. METHODS: 65 consecutive (18)F-DCFPyL PET/CT scans from 64 patients with a history of PC were analyzed...
December 8, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27927229/evaluation-of-tumor-recurrences-after-radical-prostatectomy-using-18f-choline-pet-ct-and-3t-multiparametric-mri-without-endorectal-coil-a-single-center-experience
#4
Felipe Couñago, Manuel Recio, Antonio Maldonado, Elia Del Cerro, Ana Aurora Díaz-Gavela, Israel J Thuissard, David Sanz-Rosa, Francisco José Marcos, Karmele Olaciregui, María Mateo, Laura Cerezo
BACKGROUND: To evaluate and compare the utility of 18F-fluorocholine (18F-CH) PET/CT versus 3-Tesla multiparametric MRI (mpMRI) without endorectal coil to detect tumor recurrences in patients with biochemical relapse following radical prostatectomy (RP). Secondarily, to identify possible prognostic variables associated with mpMRI and 18F-CH PET/CT findings. METHODS: Retrospective study of 38 patients who developed biochemical recurrence after RP between the years 2011 and 2015 at our institution...
December 7, 2016: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/27923396/how-we-read-fch-pet-ct-for-prostate-cancer
#5
REVIEW
Jean-Mathieu Beauregard, Alexis Beaulieu
Over the last decade, (18)F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) has gained in popularity for the staging and restaging of patients with prostate cancer (PCa). However, despite abundant literature on the topic, there is a lack of publications on how to actually interpret FCH-PET/CT in a clinical setting. Here we propose a practical, TNM-oriented approach to read FCH-PET/CT, with notes on procedure technique, image display, review sequence and report structure. The purpose of this article is to provide guidance to radiologists, nuclear medicine physicians and residents who are new to FCH-PET/CT, as well as to propose an alternate approach to more experienced physicians...
December 6, 2016: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/27922871/excellent-response-to-177lu-psma-617-radioligand-therapy-in-a-patient-with-advanced-metastatic-castration-resistant-prostate-cancer-evaluated-by-68ga-psma-pet-ct
#6
Wolfgang Roll, Axel Bode, Matthias Weckesser, Martin Bögemann, Kambiz Rahbar
Recently radiolabeled ligands targeting prostate specific membrane antigen (PSMA) have been introduced for diagnostics and treatment of prostate cancer. Labeled with Lutetium, PSMA radioligand therapy (RLT) is one of the most promising new treatments of metastatic castration refractory prostate cancer. We present images of Ga-PSMA PET/CT and parameters of response of a 75-year-old heavily pretreated metastatic castration refractory prostate cancer patient with extended bone metastases, showing an extraordinary biochemical response in PSA-levels concordant to SUV decline in bone metastases...
December 3, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27922151/-68-ga-psma-hbed-cc-pet-ct-to-differentiate-between-diffuse-bone-metastases-of-prostate-cancer-and-osteopoikilosis
#7
Florian Behrendt, Thomas Krohn, Felix Mottaghy, Frederik A Verburg
No abstract text is available yet for this article.
December 6, 2016: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/27920703/-11-c-choline-avid-but-18-f-fdg-nonavid-prostate-cancer-with-lymph-node-metastases-on-positron-emission-tomography
#8
Kazuhiro Kitajima, Kazuhito Fukushima, Shingo Yamamoto, Toshiko Yamano, Haruyuki Takaki, Koichiro Yamakado, Yukako Nakanishi, Akihiro Kanematsu, Michio Nojima, Shozo Hirota
Choline is a new positron emission tomography (PET) tracer useful for detection of prostate cancer and metastatic lesions. We report a 70-year-old man with prostate cancer and multiple abdominal, pelvic, and inguinal node metastases. PET scans demonstrated accumulation of (11)C-choline in the primary tumor and lymph node metastases but no accumulation of (18)F-FDG. Choline PET/computed tomography may be useful for diagnosis of advanced prostate cancer with suspected metastatic lesions and treatment planning...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27920097/diagnostic-performance-and-safety-of-nmk36-trans-1-amino-3-18f-fluorocyclobutanecarboxylic-acid-pet-ct-in-primary-prostate-pancer-multicenter-phase-iib-clinical-trial
#9
Hiroyoshi Suzuki, Yusuke Inoue, Hiroyuki Fujimoto, Junji Yonese, Kazunari Tanabe, Satoshi Fukasawa, Tomio Inoue, Shiro Saito, Munehisa Ueno, Akiharu Otaka
No abstract text is available yet for this article.
December 4, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27919970/11c-acetate-pet-ct-compared-to-99mtc-hdp-bone-scintigraphy-in-primary-staging-of-high-risk-prostate-cancer
#10
Sara Strandberg, Camilla Thellenberg Karlsson, Mattias Ogren, Jan Axelsson, Katrine Riklund
AIM: The aim of this study was to evaluate the detection rate of bone metastases and the added value of (11)C-acetate (ACE) positron-emission tomography/computed tomography (PET/CT) compared to bone scintigraphy (BS) in high-risk prostate cancer (PC). MATERIALS AND METHODS: A total of 66 untreated patients with high-risk PC with ACE-PET/CT and planar BS findings within 3 months of each other were retrospectively enrolled. Findings were compared and verified with follow-up data after an average of 26 months...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27914899/reply-from-authors-re-alberto-bossi-nicolas-mottet-pierre-blanchard-choline-positron-emission-tomography-computed-tomography-for-selection-of-patients-for-salvage-strategies-after-primary-local-treatment-of-prostate-cancer-and-rising-prostate-specific-antigen
#11
EDITORIAL
https://www.readbyqxmd.com/read/27912910/molecular-imaging-for-prostate-cancer-performance-analysis-of-68-ga-psma-pet-ct-versus-choline-pet-ct
#12
L Michaud, K A Touijer
INTRODUCTION: There is a need for a precise and reliable imaging to improve the management of prostate cancer. In recent years the PET/CT with choline has changed the handling of prostate cancer in Europe, and it is commonly used for initial stratification or for the diagnosis of a biochemical recurrence, although it does not lack limitations. Other markers are being tested, including the ligand of prostate-specific membrane antigen (PSMA), that seems to offer encouraging prospects. The goal of this piece of work was to critically review the role of choline and PSMA PET/CT in prostate cancer...
November 29, 2016: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/27911459/evaluation-of-bone-metastases-by-18f-choline-pet-ct-in-a-patient-with-castration-resistant-prostate-cancer-treated-with-radium-223
#13
Piera Scalzi, Cinzia Baiocco, Sabrina Genovese, Antonella Trevisan, Zuzana Sirotova, Carlo Poti
BACKGROUND: To date, bone metastases remain the main cause of morbidity and mortality in patients with metastatic castration-resistant prostate cancer (mCRPC). Therefore, the combination of accurate early detection of bony disease and effective treatment of these lesions is crucial in the management of mCRPC patients, but clinical trials specifically designed to test novel approaches are currently lacking. CASE DESCRIPTION: This report describes the case of a 74-year-old male with bone mCRPC and symptomatic and biochemical progression, who underwent radium-223 therapy, following previous treatment failure...
December 2, 2016: Urologia
https://www.readbyqxmd.com/read/27910797/staging-practice-for-prostate-cancer-varies-and-is-not-in-line-with-clinical-guidelines
#14
Lars J Petersen, Yuliya Shuytsky, Helle D Zacho
INTRODUCTION: The objective was to describe regional variations in M-staging in patients with newly diagnosed prostate cancer within a Danish county and to compare clinical practice with guideline recommendations. METHODS: Data were as captured from 1) a prospective, non-interventional study counting 635 consecutive patients referred for M-staging in the 2008-2009 period at three regional hospitals within one county, and 2) a questionnaire on M-staging practice completed by the five sites performing M-staging in the same county in 2015...
December 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27908968/psa-stratified-performance-of-18f-and-68ga-labeled-tracers-in-psma-pet-imaging-of-patients-with-biochemical-recurrence-of-prostate-cancer
#15
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
PURPOSE: Several studies outlined the sensitivity of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with (18)F offers numerous advantages, including improved image resolution, longer half-life and increased production yields. The aim of this study was to assess the PSA-stratified performance of the (18)F-labeled PSMA tracer (18)F-DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC...
December 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27906859/recent-advances-in-nuclear-medicine-in-endocrine-oncology
#16
Markus Luster, Andreas Pfestroff, Frederik A Verburg
PURPOSE OF REVIEW: The purpose is to review recent advances concerning the role of nuclear medicine in endocrine oncology. RECENT FINDINGS: For I therapy of thyroid cancer a thyrotropin (TSH) more than 30 mU/l has for many years been deemed a condition sine qua non. However, new data show that patients with lower TSH levels at the time of ablation have the same rate of successful ablation as those with TSH more than 30 mU/l.I-124 combined integrated positron emission tomography and computed X-ray tomography was shown to be highly accurate in predicting findings on posttherapy radioiodine scanning and was shown to have a high prognostic power...
January 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27906443/letter-to-the-editor-unenhanced-whole-body-mri-versus-pet-ct-for-the-detection-of-prostate-cancer-metastases-after-primary-treatment
#17
C D'Aniello, C Cavaliere, F Fiorica, G Facchini
No abstract text is available yet for this article.
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27900519/early-dynamic-imaging-in-68-ga-psma-11-pet-ct-allows-discrimination-of-urinary-bladder-activity-and-prostate-cancer-lesions
#18
Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, Josef Fritz, Boris Warwitz, Lorenza Scarpa, Llanos Geraldo Roig, Dorota Kendler, Elisabeth von Guggenberg, Jasmin Bektic, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: PET/CT with (68)Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic (68)Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder...
November 29, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27896369/detection-rate-of-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer-using-68-ga-psma-i-t-and-comparison-with-published-data-of-68-ga-psma-hbed-cc
#19
Christoph Berliner, Milena Tienken, Thorsten Frenzel, Yuske Kobayashi, Annabelle Helberg, Uve Kirchner, Susanne Klutmann, Dirk Beyersdorff, Lars Budäus, Hans-Jürgen Wester, Janos Mester, Peter Bannas
PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC. METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases...
November 28, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27893589/the-role-of-psma-pet-ct-imaging-in-restaging-of-prostate-cancer-patients-with-low-prostate-specific-antigen-levels
#20
Levent Kabasakal, Emre Demirci, Jamal Nematyazar, Reşit Akyel, Baresh Razavi, Meltem Ocak, Aslan Aygun, Can Obek, Ali R Kural
INTRODUCTION: Prostate-specific membrane antigen (PSMA) is increasingly being recognized as a novel target for the PET imaging of prostate cancer (PCa) and Ga-DKFZ-11 (Ga-PSMA) has been suggested as a novel tracer for detection of PCa relapses and metastases. The aim of this study was to evaluate the diagnostic value of PSMA PET/CT in the diagnosis of recurrent PCa with low prostate-specific antigen (PSA) levels. PATIENTS AND METHODS: We carried out a retrospective analysis of patients who underwent PSMA PET/CT from November 2013 to December 2014 in our department...
November 28, 2016: Nuclear Medicine Communications
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"